SIOC Signed Cooperation Agreement with Bayer Schering Pharma

Shanghai Institute of Organic Chemistry, CAS (SIOC) and Bayer Schering Pharma (BSP) sign the Bayer-SIOC Collaboration Agreement in Shanghai on March 3, 2010.

Dr. Hanno Wild and Dr. Kuiling Ding signed the agreement (Image by SIOC)

Prof. Dr. Hanno Wild, Senior Vice President of Global Lead Generation and Optimization, Global Drug Discovery, Bayer Schering Pharma and Prof./Dr. DING Kuiling, director of SIOC signed the agreement as representatives of BSP and SIOC. Dr. Christoph Huwe, BSP Collaboration Manager, and Dr. Jens Ackerstaff, BSP Collaboration Expert, signed the agreement in Germany late.

Both Prof. Wild and Prof. DING expressed in their later speech prospects for the next collaboration period, not only promoting close cooperation in Medicinal Chemistry, but also in other research areas, such as Organofluorine Chemistry and Organometallic Chemistry.

The collaboration between the Shanghai Institute of Organic Chemistry and Bayer Schering Pharma was established as early as 1996. The initial setup of this collaboration (in the beginning with Berlex Biosciences, a Schering AG subsidiary) focused mainly on the synthesis of large numbers of template families and scaffold analogs.

Later, the focus was shifted towards an increased variety of molecular structures, more complex syntheses, a growing share of single compounds and small scaffold series, and expanded towards synthesis of intermediates and final compounds.

Around 100 SIOC scientific staff including more than ten professors or principle investigators were involved in the collaboration over the past 14 years.